Key Inclusion Criteria:

          1. ≥18 years of age (≥20 years of age for patients enrolled in Japan)

          2. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          3. Has histologically or cytologically confirmed cancer that meets criteria as defined in
             the protocol

          4. Is anti-PD-1/PD-L1 naïve, defined as never having previously been treated with a drug
             that targets the PD-1 or PD-L1 pathway

          5. Has at least 1 lesion that meets study criteria as defined in the protocol

          6. Willing to provide tumor tissue from newly obtained biopsy (at a minimum core biopsy)
             from a tumor site that has not been previously irradiated

          7. Has adequate organ and bone marrow function as defined in the protocol

          8. In the judgement of the investigator, has a life expectancy of at least 3 months

        Key Exclusion Criteria:

          1. Is currently participating in another study of a therapeutic agent

          2. Has participated in any study of an investigational agent or an investigational device
             within 4 weeks of the first administration of study drug as defined in the protocol

          3. Has received treatment with an approved systemic therapy within 4 weeks of the first
             administration of study drug or has not yet recovered (ie, grade 1 or baseline) from
             any acute toxicities

          4. Has received recent anti-EGFR antibody therapy as defined in the protocol

          5. Has received radiation therapy or major surgery within 14 days of the first
             administration of study drug or has not recovered (ie, grade 1 or baseline) from
             adverse events

          6. Has received any previous systemic, non-immunomodulatory biologic therapy within 4
             weeks of first administration of study drug.

          7. Has had prior anti-cancer immunotherapy within 5 half-lives prior to study drug as
             defined in the protocol

          8. Has second malignancy that is progressing or requires active treatment as defined in
             the protocol

          9. Has any condition requiring ongoing/continuous corticosteroid therapy (>10 mg
             prednisone/day or anti-inflammatory equivalent) within 1-2 weeks prior to the first
             dose of study drug as defined in the protocol

         10. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease or
             any other condition that required treatment with systemic immunosuppressive treatments
             as defined in the protocol

         11. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease,
             or spinal cord compression

         12. Has encephalitis, meningitis, organic brain disease (eg, Parkinson's disease) or
             uncontrolled seizures within 1 year prior to the first dose of study drug

         13. Has any ongoing inflammatory skin disease as defined in the protocol NOTE: Other
             protocol-defined Inclusion/ Exclusion Criteria apply